XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
BUSINESS COMBINATIONS (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 29, 2021
USD ($)
shares
Nov. 05, 2021
USD ($)
$ / shares
shares
Oct. 04, 2021
USD ($)
shares
Aug. 02, 2021
USD ($)
shares
Jul. 09, 2021
USD ($)
May 03, 2021
USD ($)
shares
Apr. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
BUSINESS COMBINATIONS                    
Consideration in cash               $ 227,022    
Provision for income taxes               12,785 $ (33)  
Revenues               84,211 17,885  
Net income (loss)               (83,047) $ (366)  
HistoTox Labs                    
BUSINESS COMBINATIONS                    
Consideration in cash             $ 22,389      
Adjustments for net working capital             $ 68      
Intangible assets               $ 8,500    
HistoTox Labs | Customer Relationships                    
BUSINESS COMBINATIONS                    
Weighted-average estimated useful life               8 years    
HistoTox Labs | Non-Compete Agreements                    
BUSINESS COMBINATIONS                    
Weighted-average estimated useful life               5 years    
Bolder BioPATH                    
BUSINESS COMBINATIONS                    
Consideration in cash           $ 17,530        
Adjustments for net working capital           $ 970        
Shares issued | shares           1,588,235        
Common shares value           $ 34,452        
Principal amount           1,500        
Escrowed amount           $ 1,250        
Intangible assets               $ 12,500    
Goodwill deductible for tax purposes               $ 0    
Acquisition term               1 year    
Goodwill impairment losses               $ 0    
Bolder BioPATH | Promissory Note                    
BUSINESS COMBINATIONS                    
Annual interest rate           4.50%        
Bolder BioPATH | Customer Relationships                    
BUSINESS COMBINATIONS                    
Weighted-average estimated useful life               8 years    
Gateway Pharmacology Laboratories LLC                    
BUSINESS COMBINATIONS                    
Consideration in cash       $ 1,671            
Shares issued | shares       45,323            
Common shares value       $ 1,182            
Intangible assets               $ 100    
Goodwill deductible for tax purposes               $ 0    
HistoTox Labs, Bolder BioPATH and Plato BioPharma combined                    
BUSINESS COMBINATIONS                    
Number of operating segments | segment               1    
Revenues               $ 9,316    
Net income (loss)               $ 1,830    
Acquisition term               1 year    
Goodwill impairment losses               $ 0    
BioReliance Corporation                    
BUSINESS COMBINATIONS                    
Consideration in cash         $ 175          
Intangible assets               640    
Tangible and identifiable intangible assets               815    
Percentage of net sales from services to existing customers         10.00%         10.00%
Percentage of estimated fair value of net sales                   10.00%
Contingent consideration               $ 640   $ 640
Acquisition term               1 year    
Goodwill impairment losses               $ 0    
BioReliance Corporation | Accrued Liabilities, Current                    
BUSINESS COMBINATIONS                    
Contingent consideration                   $ 175
Plato BioPharma Inc                    
BUSINESS COMBINATIONS                    
Consideration in cash     $ 10,462              
Shares issued | shares     57,587              
Common shares value     $ 1,776              
Intangible assets               5,100    
Cash and equivalents assumed               $ 1,027    
Acquisition term               1 year    
Goodwill impairment losses               $ 0    
Plato BioPharma Inc | Promissory Note                    
BUSINESS COMBINATIONS                    
Principal amount     $ 3,000              
Envigo RMS Holding Corp                    
BUSINESS COMBINATIONS                    
Aggregate consideration paid, including adjustments for net working capital   $ 218,205                
Shares issued | shares   8,245,918                
Common shares value   $ 439,590                
Shares issuable upon the exercise of stock option | shares   790,620                
Exercisable weighted-average exercise price (in dollars per share) | $ / shares   $ 9.93                
Total value of options   $ 35,418                
Value of optioins excluded from purchase price   $ 18,242                
Share Price | $ / shares   $ 44.80                
Vested stock options reflected as purchase consideration   $ 17,176                
Intangible assets               184,000    
Cash and equivalents assumed               3,287    
Transaction costs               $ 8,491    
Acquisition term               1 year    
Goodwill impairment losses               $ 0    
Principal assumptions                    
Stock price | $ / shares   $ 53.31                
Strike price | $ / shares   $ 9.93                
Volatility   75.93%                
Expected term   3 years 18 days                
Risk-free rate   0.62%                
Robinson Services, Inc.                    
BUSINESS COMBINATIONS                    
Consideration in cash $ 3,250                  
Shares issued | shares 70,633                  
Common shares value $ 2,898